Could a common drug help fight rare bone cancers?
NCT ID NCT07321912
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether adding eflornithine (DFMO) to standard chemotherapy can help teens and young adults with Ewing sarcoma or osteosarcoma live longer without their cancer coming back. About 406 participants will join one of five groups based on their cancer type and stage. The goal is to see if this added treatment improves survival and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
RECRUITINGHershey, Pennsylvania, 17033, United States
-
St. Joseph's Children's Hospital
RECRUITINGTampa, Florida, 33614, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a targeted pill stall advanced sarcomas?
- A simple blood test may reveal how ewing sarcoma responds to therapy
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Targeted radiation zaps childhood brain tumors in early trial